Canadian application, no grantCanada
E2f ubiquitination domain, and assays for inhibitors of e2f ubiquitination
CA 2263803 A1 · Owner: Vereniging Het Nederlands Kanker Instituut · Inventors: Bernards, Rene
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The transcription factor E2F contains a ubiquitination domain. Assays for inhibitors of the domain are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 22, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 22, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 22, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledAugust 22, 1997
GrantedNo grant recorded
Term endedAugust 22, 2017
Patent numberCA 2263803 A1
Classification (IPC)C12N15/12 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.